Divalproex Sodium Tablet, Delayed Release
Product Images NDC 71335-2344

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 71335-2344). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352344)

Label for Divalproex Sodium Delayed-Release Tablets USP 500 mg by Bryant Ranch Prepack. The label shows 60 tablets in the package, repackaged by Bryant Ranch Prepack, Inc., and manufactured by Sun Pharmaceutical Industries Ltd. Storage and handling instructions are included.*

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

A vertical bar chart labeled Figure 1 showing percentage comparisons between PBO (placebo) and DVPX (Divalproex Sodium) in two studies. Study 1 uses YMRS and shows 26% for PBO and 60% for DVPX. Study 2 uses MRS and shows 29% for PBO and 58% for DVPX. Percentages are displayed above the bars, with DVPX bars marked with an asterisk.*

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

A cumulative distribution curve comparing percentage reduction in CPS rate between Divalproex Sodium (labeled as DVPX) and placebo. The x-axis shows the percentage of patients, ranging from 0 to 100. The y-axis indicates the percent reduction in CPS rate, from -100% (worsening) to 100% (improvement), with a midpoint line at 0% indicating no change.*

FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

A cumulative distribution plot labeled Figure 3 showing percent reduction in CPS rate on the vertical axis and percent of patients on the horizontal axis. Two curves compare high dose and low dose groups, with annotations indicating improvement, no change, and worsening.*

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

A bar chart titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates in two studies. The x-axis shows groups: Placebo and DVPX for Study 1, and Placebo and DVPX for Study 2. The y-axis represents the mean migraine rates, with bars indicating the mean values for each group in both studies.*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Chemical structure of Divalproex Sodium showing its molecular arrangement including sodium ion, carboxyl groups, and hydrocarbon chains as indicated by the product data.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.